
36% EBITDA Growth, But Guidance Stayed Put
CDMO · Specialty Chemicals · Niacinamide
BSE: 543271
P/L Snapshot
Q1 FY27 · standalone
Shareholding
Pattern breakdown
P/L Trends
(in crores)

CDMO · Specialty Chemicals · Niacinamide

CDMO pipeline · sequential growth · Chemical Intermediates

specialty chemicals · acetyls recovery · margin expansion
Corporate Events
Board Meeting
The 7th Annual General Meeting of the Company will be held o…
BSE Filing ↗Board Meeting
The Board of Directors of the Company approved the Company's…
BSE Filing ↗Board Meeting
The meeting of the Board of Directors is scheduled to consid…
BSE Filing ↗Board Meeting
The Board of Directors of Jubilant Ingrevia Limited recommen…
BSE Filing ↗Board Meeting
Consider and approve Unaudited Standalone and Consolidated F…
BSE Filing ↗Board Meeting
Consider and approve unaudited Financial Results
BSE Filing ↗Board Meeting
Consideration and approval of Audited Standalone and Consoli…
BSE Filing ↗Board Meeting
Consideration and approval of Interim Dividend
BSE Filing ↗Board Meeting
Consider and approve Unaudited Standalone and Consolidated F…
BSE Filing ↗